Loading grant details…
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | University of Georgia |
| Country | United States |
| Start Date | Sep 01, 2023 |
| End Date | Aug 31, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10889411 |
Grant Description
PROJECT SUMMARY: For women in the United States, breast cancer is the most common malignancy and the second leading cause of death. In this application, we focus upon a specific subtype of breast cancer known as triple-negative breast cancer (TNBC). Compared to other breast cancer subtypes, TNBC is considered more aggressive and extremely
difficult to treat with standard therapies. As a result, it has a high recurrence rate and a high overall mortality rate. TNBC accounts for up to 20% of all breast cancers, with a higher incidence in ethnic minority populations and young women (usually
All Grantees
University of Georgia
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
